Cargando…
Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin
Antibody-based immunotherapy has been effectively used for tumor treatment. However, to date, only a few tumor-associated antigens (TAAs) or therapeutic targets have been identified. Identification of more immunogenic antigens is essential for improvements in multiple myeloma (MM) diagnosis and ther...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613404/ https://www.ncbi.nlm.nih.gov/pubmed/23560043 http://dx.doi.org/10.1371/journal.pone.0059117 |
_version_ | 1782264735598641152 |
---|---|
author | Mu, Bo Zhang, Huan Cai, Xiaoming Yang, Junbao Shen, Yuewu Chen, Baofeng Liang, Suhua |
author_facet | Mu, Bo Zhang, Huan Cai, Xiaoming Yang, Junbao Shen, Yuewu Chen, Baofeng Liang, Suhua |
author_sort | Mu, Bo |
collection | PubMed |
description | Antibody-based immunotherapy has been effectively used for tumor treatment. However, to date, only a few tumor-associated antigens (TAAs) or therapeutic targets have been identified. Identification of more immunogenic antigens is essential for improvements in multiple myeloma (MM) diagnosis and therapy. In this study, we synthesized a polyclonal antibody (PAb) by immunizing rabbits with whole human plasmacytoma ARH-77 cells and identified MM-associated antigens, including enlonase, adipophilin, and HSP90s, among others, via proteomic technologies. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that 200 µg/mL PAb inhibits the proliferation of ARH-77 cells by over 50% within 48 h. Flow cytometric assay indicated that PAb treatment significantly increases the number of apoptotic cells compared with other treatments (52.1% vs. NS, 7.3% or control rabbit IgG, 9.9%). In vivo, PAb delayed tumor growth and prolonged the lifespan of mice. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed that PAb also induces statistically significant changes in apoptosis compared with other treatments (P<0.05). We therefore conclude that PAb could be used for the effective screening and identification of TAA. PAb may have certain anti-tumor functions in vitro and in vivo. As such, its combination with proteomic technologies could be a promising approach for sieving TAA for the diagnosis and therapy of MM. |
format | Online Article Text |
id | pubmed-3613404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36134042013-04-04 Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin Mu, Bo Zhang, Huan Cai, Xiaoming Yang, Junbao Shen, Yuewu Chen, Baofeng Liang, Suhua PLoS One Research Article Antibody-based immunotherapy has been effectively used for tumor treatment. However, to date, only a few tumor-associated antigens (TAAs) or therapeutic targets have been identified. Identification of more immunogenic antigens is essential for improvements in multiple myeloma (MM) diagnosis and therapy. In this study, we synthesized a polyclonal antibody (PAb) by immunizing rabbits with whole human plasmacytoma ARH-77 cells and identified MM-associated antigens, including enlonase, adipophilin, and HSP90s, among others, via proteomic technologies. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that 200 µg/mL PAb inhibits the proliferation of ARH-77 cells by over 50% within 48 h. Flow cytometric assay indicated that PAb treatment significantly increases the number of apoptotic cells compared with other treatments (52.1% vs. NS, 7.3% or control rabbit IgG, 9.9%). In vivo, PAb delayed tumor growth and prolonged the lifespan of mice. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed that PAb also induces statistically significant changes in apoptosis compared with other treatments (P<0.05). We therefore conclude that PAb could be used for the effective screening and identification of TAA. PAb may have certain anti-tumor functions in vitro and in vivo. As such, its combination with proteomic technologies could be a promising approach for sieving TAA for the diagnosis and therapy of MM. Public Library of Science 2013-04-01 /pmc/articles/PMC3613404/ /pubmed/23560043 http://dx.doi.org/10.1371/journal.pone.0059117 Text en © 2013 Mu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Mu, Bo Zhang, Huan Cai, Xiaoming Yang, Junbao Shen, Yuewu Chen, Baofeng Liang, Suhua Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin |
title | Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin |
title_full | Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin |
title_fullStr | Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin |
title_full_unstemmed | Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin |
title_short | Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin |
title_sort | screening of multiple myeloma by polyclonal rabbit anti-human plasmacytoma cell immunoglobulin |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613404/ https://www.ncbi.nlm.nih.gov/pubmed/23560043 http://dx.doi.org/10.1371/journal.pone.0059117 |
work_keys_str_mv | AT mubo screeningofmultiplemyelomabypolyclonalrabbitantihumanplasmacytomacellimmunoglobulin AT zhanghuan screeningofmultiplemyelomabypolyclonalrabbitantihumanplasmacytomacellimmunoglobulin AT caixiaoming screeningofmultiplemyelomabypolyclonalrabbitantihumanplasmacytomacellimmunoglobulin AT yangjunbao screeningofmultiplemyelomabypolyclonalrabbitantihumanplasmacytomacellimmunoglobulin AT shenyuewu screeningofmultiplemyelomabypolyclonalrabbitantihumanplasmacytomacellimmunoglobulin AT chenbaofeng screeningofmultiplemyelomabypolyclonalrabbitantihumanplasmacytomacellimmunoglobulin AT liangsuhua screeningofmultiplemyelomabypolyclonalrabbitantihumanplasmacytomacellimmunoglobulin |